文献速递胸部肿瘤放疗放疗物理与技术

动态FDG PET与CT灌注预测肺癌SABR后病理完全缓解

Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study.
PubMed 文献 · Radiat Oncol · 2021-01-13

模型基于SABR前肿瘤血容量(BVpre-SABR)和SUVmax变化(ΔSUVmax)分为三组,预测pCR的一致性达0.92(P=0.03),优于RECIST(0.54)和PERCIST(0.58)。

要点

  • SABR前BV<9.3 mL/100 g且ΔSUVmax<-48.9%组真pCR率最高达92%。
  • BVpre-SABR≥9.3 mL/100 g组真pCR率为0%。
  • RPA模型预测pCR一致性0.92,显著优于RECIST和PERCIST。

核心结论

  • 基于动态[18F]FDG-PET和CT灌注的预测模型预测NSCLC对SABR的pCR显著优于RECIST和PERCIST。
  • 模型使用BVpre-SABR和ΔSUVmax,分别与肿瘤微血管密度和细胞增殖相关,需更大样本验证。

研究设计与样本

  • SABR前和SABR后8周行动态[18F]FDG-PET和CT灌注成像检查。
  • 采用递归分区分析(RPA)建立基于PET和CTP成像生物标志物的pCR预测模型,并与RECIST 1.1和PERCIST 1.0比较。

主要发现

  • RPA基于BVpre-SABR和ΔSUVmax识别出三个应答组,阈值分别为BVpre-SABR=9.3 mL/100 g和ΔSUVmax=-48.9%。
  • BVpre-SABR<9.3 mL/100 g且ΔSUVmax<-48.9%组真pCR率最高为92%。
  • BVpre-SABR≥9.3 mL/100 g组真pCR率最差为0%。
  • RPA模型预测pCR一致性为0.92(P=0.03)。
  • RECIST和PERCIST预测pCR一致性分别为0.54和0.58。

关键数值与推荐

  • RPA模型阈值:BVpre-SABR=9.3 mL/100 g,ΔSUVmax=-48.9%。
  • 最高真pCR率92%见于BVpre-SABR<9.3 mL/100 g且ΔSUVmax<-48.9%组。
  • 真pCR率0%见于BVpre-SABR≥9.3 mL/100 g组。
  • RPA模型一致性0.92(P=0.03),RECIST一致性0.54,PERCIST一致性0.58。

临床怎么用

  • SABR前CT灌注测得的BV和SABR后8周动态PET的ΔSUVmax可用于预测pCR,辅助疗效评估。
  • 该模型预测pCR优于传统RECIST和PERCIST标准,但需更大样本验证后方可用于临床决策。

局限性

  • 研究为预设二次分析,非独立主要终点研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult. This prospective study aimed to develop a predictive model for true pathologic complete response (pCR) to SABR using imaging-based biomarkers from dynamic [18F]FDG-PET and CT Perfusion (CTP). METHODS: Twenty-six patients with early-stage NSCLC treated with SABR followed by surgical resection were included, as a pre-specified secondary analysis of a larger study. Dynamic [18F]FDG-PET and CTP were performed pre-SABR and 8-week post. Dynamic [18F]FDG-PET provided maximum and mean standardized uptake value (SUV) and kinetic parameters estimated using a previously developed flow-modified two-tissue compartment model while CTP measured blood flow, blood volume and vessel permeability surface product. Recursive partitioning analysis (RPA) was used to establish a predictive model with the measured PET and CTP imaging biomarkers for predicting pCR. The model was compared to current RECIST (Response Evaluation Criteria in Solid Tumours version 1.1) and PERCIST (PET Response Criteria in Solid Tumours version 1.0) criteria. RESULTS: RPA identified three response groups based on tumour blood volume before SABR (BVpre-SABR) and change in SUVmax (ΔSUVmax), the thresholds being BVpre-SABR = 9.3 mL/100 g and ΔSUVmax = - 48.9%. The highest true pCR rate of 92% was observed in the group with BVpre-SABR < 9.3 mL/100 g and ΔSUVmax < - 48.9% after SABR while the worst was observed in the group with BVpre-SABR ≥ 9.3 mL/100 g (0%). RPA model achieved excellent pCR prediction (Concordance: 0.92; P = 0.03). RECIST and PERCIST showed poor pCR prediction (Concordance: 0.54 and 0.58, respectively). CONCLUSIONS: In this study, we developed a predictive model based on dynamic [18F]FDG-PET and CT Perfusion imaging that was significantly better than RECIST and PERCIST criteria to predict pCR of NSCLC to SABR. The model used BVpre-SABR and ΔSUVmax which correlates to tumour microvessel density and cell proliferation, respectively and warrants validation with larger sample size studies. TRIAL REGISTRATION: MISSILE-NSCLC, NCT02136355 (ClinicalTrials.gov). Registered May 8, 2014, https://clinicaltrials.gov/ct2/show/NCT02136355.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yang DM, Palma DA, Kwan K, et al. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study. Radiat Oncol. 2021. PMID: 33441162. doi:10.1186/s13014-021-01747-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。